Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.56M Buy
230,993
+78,119
+51% +$2.04M 0.04% 367
2026
Q1
$4.29M Buy
152,874
+16,879
+12% +$449K 0.04% 395
2025
Q4
$3.39M Buy
135,995
+39,539
+41% +$997K 0.03% 422
2025
Q3
$2.46M Buy
96,456
+25,464
+36% +$629K 0.02% 506
2025
Q2
$1.72M Sell
70,992
-9,422
-12% -$220K 0.02% 547
2025
Q1
$2.04M Buy
80,414
+71,082
+762% +$1.86M 0.03% 478
2024
Q4
$248K Buy
+9,332
New +$253K ﹤0.01% 1245
2024
Q3
– Sell
-95,822
Closed -$2.68M – 1518
2024
Q2
$2.68M Buy
+95,822
New +$2.64M 0.07% 281
2024
Q1
– Sell
-55,541
Closed -$1.6M – 1381
2023
Q4
$1.6M Sell
55,541
-3,952
-7% -$119K 0.04% 431
2023
Q3
$1.97M Buy
+59,493
New +$2.1M 0.06% 312

Other funds holding PFE

Vident Advisory's PFE Position: Q2 2026 in Review

Vident Advisory increased its Pfizer (PFE) stake by 51% in Q2 2026, buying an estimated $2.04M and bringing the position to 230,993 shares worth $5.56M. The position accounts for 0.04% of the portfolio, ranked #367.

Vident Advisory first reported a position in PFE in Q3 2023 and has held it in 10 quarters since. 2,841 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Vident Advisory held 230,993 shares of Pfizer worth $5.56M as of Q2 2026.
  • Vident Advisory bought 78,119 Pfizer shares in Q2 2026, an estimated $2.04M.
  • Pfizer made up 0.04% of Vident Advisory's portfolio in Q2 2026, its #367 holding.
  • Vident Advisory first reported a position in Pfizer in Q3 2023 and has held it in 10 quarters since.
  • 2,841 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.